Eloxx begins Alport syndrome drug trial
Eloxx Pharmaceuticals (NASDAQ:ELOX) dosed the first two patients in the EXACT Study, a Phase 2b clinical trial evaluating exaluren in patients with nonsense mutation Alport syndrome.

TV presenter and finance editor at Grafa, with a Master’s in Commerce from UWA and diverse industry experience in finance, insurance, and media.
Eloxx Pharmaceuticals (NASDAQ:ELOX) dosed the first two patients in the EXACT Study, a Phase 2b clinical trial evaluating exaluren in patients with nonsense mutation Alport syndrome.
Lazard (NYSE:LAZ) reported preliminary assets under management of $290.3 billion as of August 31, 2026, up from $286.9 billion at the end of July.
Hooker Furnishings (NASDAQ:HOFT) reported a profitable second quarter of fiscal 2027, with net income reaching $1.7 million after benefiting from tariff recoveries and previous cost reductions.
Rocket Lab (NASDAQ:RKLB) completed its 16th Electron launch of 2026, successfully deploying an Earth observation satellite for a confidential customer from Launch Complex 1 in New Zealand.
Russia has made tax identification numbers mandatory for clients opening digital-depository accounts for cryptocurrency and digital rights.
Ripple has expanded its GSmart treasury platform with policy-controlled AI agents covering financial forecasting, liquidity, risk, reconciliation and reporting.
Voltaic Strategic Resources (ASX:VSR) identified malachite-rich material across an area of approximately 100m during initial field work at its El Dinero prospect.
Trezor has warned users about phishing emails sent through its compromised third-party email infrastructure.
Bitcoin Bancorp has agreed to buy 2,547 Bitcoin Depot ATMs for US$620,750.
MoneyGram has launched its first stablecoin-backed card in Colombia, with USDC available at launch.
Got a second for a cookie? 🍪Essential cookies keep Grafa running smoothly. A few optional ones help us see what's working so we can make it better. You're in control — change your mind any time. Cookie policy · Privacy policy